Connecticut lawmakers have now added chronic neuropathic pain associated with degenerative spinal disorders as a qualifying condition for medical marijuana, making it the 31st condition approved for treatment with medicinal cannabis.
Alongside this, the General Assembly’s Regulations Review Committee also agreed to update the Connecticut state laws to reflect the FDA’s recent approval of CBD-based EPIDIOLEX from GW Pharmaceuticals plc (NASDAQ:GWPH).
As of November 11th, Connecticut had 29,561 registered patients and 1,003 registered physicians in its medical marijuana program.
Be sure to subscribe to Connecticut Marijuana News Updates here so you never miss an important update!
Get Real-Time Updates from The Daily Marijuana Observer
